Pharmabiz2d
Teva Pharma, Medincell announce US FDA acceptance of sNDA for Uzedy to treat people living with schizophrenia
Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) 2024 Financial Results Earnings Call Transcript
Proof of Rovi’s commitment to a sustainable business model is the recognition obtained by the company through the evaluation by Sustainalytics. In December 2024, Rovi obtained the fifth position in ...
Pharm Exec2d
FDA Accepts Supplemental New Drug Application for Teva, Medincell’s Uzedy for Bipolar I Disorder
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
Investing3d
FDA accepts Teva, Medincell's supplemental application for UZEDY as bipolar I disorder treatment
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...
Investing3d
FDA accepts Teva, Medincell's supplemental application for UZEDY as bipolar I disorder treatment
TV46000-CNS-30072 (the RISE Study – The Risperidone Subcutaneous Extended-Release Study) and TV46000-CNS-30078 (the SHINE Study – Safety in Humans of TV-46000 sc INjection Evaluation).
pharmaphorum5d
Teva: looking for innovation and growth in ‘space between’ branded and generics
Teva is developing Risperidone LAI, which only needs to ... rather than the intramuscular injection into the buttock needed for existing 'depot' formulations. Indeed, other companies have already ...
Teva, Medincell announce FDA acceptance of sNDA for Uzedy
Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...